Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Overman

Showing results (191-200 of 265) with videos related to

Pageof 27
Sort By:
JCO Precision Oncology|February 1, 2022
Validation of <i>HER2</i> Amplification as a Predictive Biomarker for Anti-Epidermal Growth Factor Receptor Antibody Therapy in Metastatic Colorectal CancerKanwal Raghav, Jonathan M Loree, Jeffrey S Morris, et al.
European Journal of Cancer (Oxford, England : 1990)|October 12, 2023
Endoscopic and imaging outcomes of PD-1 therapy in localised dMMR colorectal cancerDaniel A Fox, Deepak Bhamidipati, Tsuyoshi Konishi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 8, 2021
ARID1A Mutation May Define an Immunologically Active Subgroup in Patients with Microsatellite Stable Colorectal CancerAmir Mehrvarz Sarshekeh, Jumanah Alshenaifi, Jason Roszik, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 22, 2008
Pathologic response to preoperative chemotherapy: a new outcome end point after resection of hepatic colorectal metastasesDan G Blazer, Yoji Kishi, Dipen M Maru, et al.
JCO Precision Oncology|July 12, 2021
Comprehensive Clinical and Molecular Characterization of <i>KRAS</i> <sup>G12C</sup>-Mutant Colorectal CancerJason T Henry, Oluwadara Coker, Saikat Chowdhury, et al.
Annals of Surgical Oncology|December 10, 2025
Hepatectomy Plus Chemotherapy or Chemotherapy Alone for Resectable Liver and Unresectable Lung Metastases from Colorectal Adenocarcinoma (LUNA): A Randomized Phase II TrialIan W Folkert, Reza Mehran, Ryan Sun, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 29, 2015
Characterizing the patterns of clonal selection in circulating tumor DNA from patients with colorectal cancer refractory to anti-EGFR treatmentM P Morelli, M J Overman, A Dasari, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 6, 2016
Utility of a molecular prescreening program in advanced colorectal cancer for enrollment on biomarker-selected clinical trialsM J Overman, V Morris, B Kee, et al.
Plos One|March 8, 2017
Association of SMAD4 mutation with patient demographics, tumor characteristics, and clinical outcomes in colorectal cancerAmir Mehrvarz Sarshekeh, Shailesh Advani, Michael J Overman, et al.
Science Translational Medicine|August 10, 2022
Adenoviral-based vaccine promotes neoantigen-specific CD8<sup>+</sup> T cell stemness and tumor rejectionAnna Morena D'Alise, Nadia Brasu, Carlo De Intinis, et al.
Pageof 27

Showing results (191-200 of 265) with videos related to

Sort By:
Pageof 27
JCO Precision Oncology|February 1, 2022
Validation of <i>HER2</i> Amplification as a Predictive Biomarker for Anti-Epidermal Growth Factor Receptor Antibody Therapy in Metastatic Colorectal CancerKanwal Raghav, Jonathan M Loree, Jeffrey S Morris, et al.
European Journal of Cancer (Oxford, England : 1990)|October 12, 2023
Endoscopic and imaging outcomes of PD-1 therapy in localised dMMR colorectal cancerDaniel A Fox, Deepak Bhamidipati, Tsuyoshi Konishi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 8, 2021
ARID1A Mutation May Define an Immunologically Active Subgroup in Patients with Microsatellite Stable Colorectal CancerAmir Mehrvarz Sarshekeh, Jumanah Alshenaifi, Jason Roszik, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 22, 2008
Pathologic response to preoperative chemotherapy: a new outcome end point after resection of hepatic colorectal metastasesDan G Blazer, Yoji Kishi, Dipen M Maru, et al.
JCO Precision Oncology|July 12, 2021
Comprehensive Clinical and Molecular Characterization of <i>KRAS</i> <sup>G12C</sup>-Mutant Colorectal CancerJason T Henry, Oluwadara Coker, Saikat Chowdhury, et al.
Annals of Surgical Oncology|December 10, 2025
Hepatectomy Plus Chemotherapy or Chemotherapy Alone for Resectable Liver and Unresectable Lung Metastases from Colorectal Adenocarcinoma (LUNA): A Randomized Phase II TrialIan W Folkert, Reza Mehran, Ryan Sun, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 29, 2015
Characterizing the patterns of clonal selection in circulating tumor DNA from patients with colorectal cancer refractory to anti-EGFR treatmentM P Morelli, M J Overman, A Dasari, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 6, 2016
Utility of a molecular prescreening program in advanced colorectal cancer for enrollment on biomarker-selected clinical trialsM J Overman, V Morris, B Kee, et al.
Plos One|March 8, 2017
Association of SMAD4 mutation with patient demographics, tumor characteristics, and clinical outcomes in colorectal cancerAmir Mehrvarz Sarshekeh, Shailesh Advani, Michael J Overman, et al.
Science Translational Medicine|August 10, 2022
Adenoviral-based vaccine promotes neoantigen-specific CD8<sup>+</sup> T cell stemness and tumor rejectionAnna Morena D'Alise, Nadia Brasu, Carlo De Intinis, et al.
Pageof 27